lixisenatide vs Semaglutide (Rybelsus)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi and partners
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)
Result source: NCT00707031
Semaglutide (Rybelsus)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT06050577 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | lixisenatide | Semaglutide (Rybelsus) |
|---|---|---|
| HbA1c, change | -0.6% vs 0.1%−0.6 vs placeboNCT0179870619 other results
| -1.6% vs -0.2%−1.4 vs placeboNCT0410954734 other results
|
| Body weight, change (kg) | -0.6 vs 1.0vs Insulin GlulisineNCT0176855917 other results
| -4.2 vs -1.3−2.9 vs placeboNCT0391432639 other results
|
| HbA1c below 7% | 53% vs 38.8%+14.2 vs placeboNCT0116977910 other results
| —Not posted · NCT07271251 |
| Fasting plasma glucose, change | -0.3 vs 0.0−0.3 vs placeboNCT0179870617 other results
| -1.9 vs -0.2−1.7 vs placeboNCT0290693039 other results
|
| 3-point MACE (% with event) | —Not reported | 12% vs 13.8%−1.8 vs placeboNCT039143261 other result
|
HbA1c, change
- lixisenatide
- -0.6% vs 0.1%−0.6 vs placeboNCT01798706
19 other results
- -0.8% vs -0.5% NCT01169779
- -0.7% vs -0.4% NCT00975286
- -0.9% vs -0.3% NCT00763815
- -0.7% vs -0.4% NCT00715624
- -0.8% vs -0.1% NCT00713830
- -0.8% vs -0.4% NCT00763451
- -0.9% vs -0.4% NCT00763451
- -0.8% vs 0.1% NCT00866658
- -0.6% vs -0.8% NCT01768559
- -0.8% vs -1.0% NCT00707031
- -1.9% vs -1.7% NCT05413369
- -1.1% vs -0.6% NCT02058160
- -1.6% vs -1.3% NCT02058147
- -0.8% vs -1.3% NCT02058147
- -1.9% vs -1.7% NCT05413369
- -0.7% vs -0.7% NCT00976937
- -1.8% vs -1.6% NCT01476475
- -0.6% vs -0.7% NCT01596504
- -0.3% vs -0.5% NCT01175473
- Semaglutide (Rybelsus)
- -1.6% vs -0.2%−1.4 vs placeboNCT04109547
34 other results
- -1.5% vs -0.2% NCT04109547
- -1.1% vs -0.2% NCT04109547
- -0.7% vs -0.1% NCT03914326
- -1% vs -0.3% NCT02692716
- -1.2% vs -0.1% NCT02863419
- -1.2% vs -0.2% NCT03021187
- -0.9% vs -0.2% NCT03021187
- -0.6% vs -0.2% NCT03021187
- -1.5% vs 0.1% NCT03018028
- -1.4% vs 0.1% NCT03018028
- -1% vs 0.1% NCT03018028
- -2% vs -1.6% NCT03015220
- -1.3% vs -0.9% NCT02863328
- -1.2% vs -0.7% NCT02607865
- -1.1% vs -0.7% NCT02607865
- -1% vs -0.7% NCT02607865
- -0.9% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -0.6% vs -0.7% NCT02607865
- -1.8% vs -1.4% NCT03015220
- -1.7% vs -1.6% NCT03015220
- -1.4% vs -1.4% NCT03015220
- -1.1% vs -1.6% NCT03015220
- -0.8% vs -1.4% NCT03015220
- -1.3% vs -0.8% NCT02849080
- -0.2% vs 0% NCT02849080
- -2.0% vs -0.4% NCT01923181
- -1.8% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.7% vs -0.4% NCT01923181
- -1.6% vs -0.4% NCT01923181
- -1.2% vs -0.4% NCT01923181
- -0.9% vs -0.4% NCT01923181
- -1.2% vs -1.0% NCT05035082
Body weight, change (kg)
- lixisenatide
- -0.6 vs 1.0vs Insulin GlulisineNCT01768559
17 other results
- -1.5 vs -0.2 NCT01798706
- -1.5 vs -1.2 NCT01169779
- 0.3 vs 1.2 NCT00975286
- -0.2 vs 0.2 NCT00763815
- -1.8 vs -0.5 NCT00715624
- -1.8 vs -0.9 NCT00713830
- -2.7 vs -1.6 NCT00763451
- -2.6 vs -1.6 NCT00763451
- -0.4 vs 0.1 NCT00866658
- -3.0 vs -4.0 NCT00707031
- -0.3 vs 1.2 NCT05413369
- -0.7 vs 0.7 NCT02058160
- -0.3 vs 1.1 NCT02058147
- -2.5 vs -1.2 NCT00976937
- -2.3 vs 1.1 NCT02058147
- -1.0 vs 0.5 NCT01476475
- -1.6 vs -2.4 NCT01596504
- Semaglutide (Rybelsus)
- -4.2 vs -1.3−2.9 vs placeboNCT03914326
39 other results
- -4.2 vs -0.8 NCT02692716
- -3.1 vs -1.1 NCT04109547
- -4.4 vs -1 NCT02863419
- -3.8 vs 0.5 NCT03021187
- -2.4 vs -1.1 NCT03018028
- -2.9 vs -1 NCT03018028
- -2.2 vs -1.1 NCT04109547
- -2.2 vs 0.5 NCT03021187
- -1.1 vs -1.1 NCT04109547
- -0.9 vs 0.5 NCT03021187
- -1.2 vs -1.1 NCT03018028
- -0.8 vs -1 NCT03018028
- -0.4 vs -1.1 NCT03018028
- 0 vs -1 NCT03018028
- -3.8 vs -0.5 NCT04017832
- -4 vs -3.7 NCT02863328
- -3.5 vs -0.7 NCT02607865
- -3.2 vs -1 NCT02607865
- -2.9 vs -0.5 NCT04017832
- -2.5 vs -0.7 NCT02607865
- -2.8 vs -1 NCT02607865
- -2.2 vs 0.3 NCT03015220
- -1.7 vs 1 NCT03015220
- -0.9 vs 1 NCT03015220
- -1.4 vs -0.5 NCT04017832
- -1.6 vs -0.7 NCT02607865
- -1.8 vs -1 NCT02607865
- -1 vs 0.3 NCT03015220
- -0.1 vs 0.3 NCT03015220
- 0 vs 1 NCT03015220
- -2.6 vs -0.9 NCT02849080
- -6.9 vs -1.2 NCT01923181
- -5.9 vs -1.2 NCT01923181
- -8.3 vs -1.2 NCT01923181
- -5.8 vs -1.2 NCT01923181
- -4.9 vs -1.2 NCT01923181
- -2.9 vs -1.2 NCT01923181
- -2.0 vs -1.2 NCT01923181
- -3.9 vs -3.5 NCT05035082
HbA1c below 7%
- lixisenatide
- 53% vs 38.8%+14.2 vs placeboNCT01169779
10 other results
- 56.3% vs 38.5% NCT00975286
- 52.3% vs 26.4% NCT00763815
- 28.3% vs 12% NCT00715624
- 36.4% vs 13.5% NCT00713830
- 42.1% vs 24.1% NCT00763451
- 47.4% vs 24.1% NCT00763451
- 35.6% vs 5.2% NCT00866658
- 48.5% vs 49.8% NCT00707031
- 72.5% vs 59.8% NCT05413369
- 40.7% vs 40% NCT00976937
- Semaglutide (Rybelsus)
- —Not posted · NCT07271251
Fasting plasma glucose, change
- lixisenatide
- -0.3 vs 0.0−0.3 vs placeboNCT01798706
17 other results
- -0.7 vs -0.2 NCT01169779
- 0.3 vs 0.5 NCT00975286
- -1.2 vs -0.3 NCT00763815
- -0.6 vs -0.6 NCT00715624
- -1.0 vs -0.4 NCT00713830
- -0.6 vs 0.1 NCT00763451
- -0.5 vs 0.1 NCT00763451
- -0.4 vs 0.3 NCT00866658
- -0.2 vs -0.2 NCT01768559
- -1.2 vs -1.4 NCT00707031
- -3.2 vs -3.5 NCT05413369
- -0.3 vs -0.5 NCT02058160
- -3.5 vs -3.3 NCT02058147
- -0.5 vs -0.7 NCT00976937
- -1.5 vs -3.3 NCT02058147
- -3.4 vs -3.5 NCT01476475
- 0.1 vs 0.1 NCT01596504
- Semaglutide (Rybelsus)
- -1.9 vs -0.2−1.7 vs placeboNCT02906930
39 other results
- -2.0 vs -0.3 NCT02863419
- -1.6 vs -0.3 NCT02827708
- -1.4 vs 0.5 NCT03021187
- -1.9 vs -0.7 NCT02863419
- -1.6 vs -0.1 NCT03021187
- -1.5 vs -0.2 NCT02906930
- -1.1 vs 0.5 NCT03021187
- -1.1 vs -0.1 NCT03021187
- -0.9 vs -0.2 NCT02906930
- -0.5 vs 0.5 NCT03021187
- -0.8 vs -0.1 NCT03021187
- -2.4 vs -0.4 NCT03018028
- -2.3 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.6 vs 0.3 NCT03018028
- -1.6 vs -0.4 NCT03018028
- -1.1 vs 0.3 NCT03018028
- -2.0 vs -2.1 NCT02863328
- -1.7 vs -0.9 NCT02607865
- -2 vs -0.5 NCT04017832
- -2.0 vs -2.1 NCT02863328
- -1.8 vs -1.0 NCT02607865
- -1.6 vs -0.9 NCT02607865
- -1.2 vs -0.9 NCT02607865
- -1.8 vs -0.5 NCT04017832
- -1.3 vs -1.0 NCT02607865
- -1.1 vs -0.9 NCT02607865
- -0.8 vs -0.9 NCT02607865
- -2.2 vs -1.8 NCT03015220
- -2.0 vs -1.8 NCT03015220
- -1.0 vs -0.5 NCT04017832
- -1.0 vs -1.0 NCT02607865
- -1.1 vs -0.9 NCT02607865
- -2.7 vs -2.2 NCT03015220
- -2.3 vs -2.2 NCT03015220
- -1.2 vs -2.2 NCT03015220
- -0.9 vs -1.8 NCT03015220
- -2.4 vs -1.4 NCT02849080
- -0.3 vs 0.0 NCT02849080
3-point MACE (% with event)
- lixisenatide
- —Not reported
- Semaglutide (Rybelsus)
- 12% vs 13.8%−1.8 vs placeboNCT03914326
1 other result
- 3.8% vs 4.8% NCT02692716
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety
Coverage. lixisenatide: 15 of 15 rows · Semaglutide (Rybelsus): 14 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | lixisenatide Rows use multiple source trials | Semaglutide (Rybelsus) Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.57 mmol/L @ 24wka,b,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.35 mmol/L @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -39.4 mmol/L @ 104wkb,c,d NCT02849080 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.74% (n=222) @ 24wka,b,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.65% (n=218) @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -1.3% (n=180) @ 104wkb,c,d NCT02849080 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 40.6% (n=239) @ 24wka,b,c,e NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose43% (n=244) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 39.2% (n=536) @ 68wk14 mg once dailya,b,c,e NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses58.9% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 49.9% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants No placebo or comparator arm | 19.2% (n=239) @ 24wka,b,c,e NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose23.8% (n=244) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 23.6% (n=536) @ 68wk14 mg once dailya,b,c,e NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses46.2% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 35.8% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| PPG Excursion absolute change · mmol/L | -3.42 vs -1.59 Insulin Glulisine mmol/L @ 26wkb,c NCT01768559 · Phase 3 · registry result, not featured evidence | -1.2 vs -0.3 placebo mmol/L @ 26wk14 mga,b,c NCT02906930 · Phase 3 show 2 more doses-0.8 vs -0.3 placebo mmol/L @ 26wk7 mg NCT02906930 · Phase 3 -0.4 vs -0.3 placebo mmol/L @ 26wk3 mg NCT02906930 · Phase 3 |
| PPG Excursion absolute change · mg/dL | -70.43 vs -24.93 Liraglutide mg/dL @ 4wkf,b,c,g NCT01175473 · Phase 2 · registry result, not featured evidence | -27.9 vs -6.7 placebo mg/dL @ 26wk14 mga,f,b,c,g NCT04109547 · Phase 3 · registry result, not featured evidence show 2 more doses-20 vs -6.7 placebo mg/dL @ 26wk7 mg NCT04109547 · Phase 3 · registry result, not featured evidence -14.5 vs -6.7 placebo mg/dL @ 26wk3 mg NCT04109547 · Phase 3 · registry result, not featured evidence |
| SMBG 7-point absolute change · mmol/L | -0.784 vs -0.782 Insulin Glulisine mmol/L @ 26wkb,c NCT01768559 · Phase 3 · registry result, not featured evidence | -2.3 vs -0.5 placebo mmol/L @ 26wk14 mga,b,c NCT02906930 · Phase 3 show 2 more doses-2.1 vs -0.5 placebo mmol/L @ 26wk7 mg NCT02906930 · Phase 3 -1.8 vs -0.5 placebo mmol/L @ 26wk3 mg NCT02906930 · Phase 3 |
| TDDI Change Units Per absolute change · per day | -1.39 vs -0.11 placebo per day @ 24wkb,c,h NCT00866658 · Phase 3 · registry result, not featured evidence | -5 vs 8 placebo per day @ 52wk14 mga,b,c,h NCT03021187 · Phase 3 show 2 more doses-8 vs 8 placebo per day @ 52wk7 mg NCT03021187 · Phase 3 1 vs 8 placebo per day @ 52wk3 mg NCT03021187 · Phase 3 |
| Waist Circumference Change absolute change · cm | -1.4 vs -1.93 Liraglutide cm @ 8wk20 µgf,b,c,i NCT01596504 · Phase 2 · registry result, not featured evidence | -1.8 vs -0.9 Sitagliptin cm @ 104wkf,b,c,i NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg No placebo or comparator arm | -2.8 kg @ 24wka,b,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-2.6 kg @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence | -3.7 kg @ 104wkb,c,d NCT02849080 · Phase 3 · registry result, not featured evidence |
| Weight Loss 5% responder rate · % of participants No placebo or comparator arm | 19.3% (n=249) @ 24wka,b,c,e NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose14.9% (n=248) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence | 42.2% (n=536) @ 68wk14 mg once dailya,b,c,e NCT04707469 · Phase 3 · registry result, not featured evidence show 2 more doses65.7% (n=535) @ 68wk50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 58.5% (n=535) @ 68wk25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 32.5%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.2%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 8.3%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 3.5% NCT01147250 · Phase 3 11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 5.8% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 10.5%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 12.4%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 11.9% NCT01798706 · Phase 3 · registry result, not featured evidence 10.1% NCT01768559 · Phase 3 · registry result, not featured evidence 10.6%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 16%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 8.7% NCT01169779 · Phase 3 · registry result, not featured evidence 13% NCT00975286 · Phase 3 · registry result, not featured evidence 26% NCT00763815 · Phase 3 · registry result, not featured evidence 27.5%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 22.4%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 10.1% NCT00976937 · Phase 3 · registry result, not featured evidence 35.3% NCT00715624 · Phase 3 · registry result, not featured evidence 30.9% NCT00713830 · Phase 3 · registry result, not featured evidence 18.6%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 24.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 25%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 39.4%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 13.6% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 4.2%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 6.8% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence | 6.9%14 mgk NCT02906930 · Phase 3 show 39 more results8%7 mg NCT02906930 · Phase 3 3.4%3 mg NCT02906930 · Phase 3 2.7%14 mg NCT02863328 · Phase 3 5.8%14 mg NCT02607865 · Phase 3 6.4%7 mg NCT02607865 · Phase 3 7.1%3 mg NCT02607865 · Phase 3 2.8%14 mg NCT02863419 · Phase 3 3.1%14 mg NCT02827708 · Phase 3 3.3%14 mg NCT03021187 · Phase 3 4.9%7 mg NCT03021187 · Phase 3 5.4%3 mg NCT03021187 · Phase 3 1.5% NCT03914326 · Phase 3 0.3% NCT02692716 · Phase 3 11.8% NCT05035082 · Phase 4 · registry result, not featured evidence 5.4%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 5.6%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.4%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 7.2%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 5%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.6%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 3.1%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 2.1%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 0%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 2.3%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.5%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 2.3%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 11.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 11.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 5.7%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 8.6%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 14.1%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results2.5%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 4.2%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 — NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.3% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 3.9%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence — NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 8.5% NCT01798706 · Phase 3 · registry result, not featured evidence 5% NCT01768559 · Phase 3 · registry result, not featured evidence 4.9%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 4.4%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 5.6% NCT01169779 · Phase 3 · registry result, not featured evidence 8.5% NCT00975286 · Phase 3 · registry result, not featured evidence 9% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 2.5% NCT00976937 · Phase 3 · registry result, not featured evidence 11.2% NCT00715624 · Phase 3 · registry result, not featured evidence 12.4% NCT00713830 · Phase 3 · registry result, not featured evidence 8.7%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 11.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 13.9%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 21.2%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 9.1% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 2.1%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 3.7% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence | —14 mgk NCT02906930 · Phase 3 show 39 more results—7 mg NCT02906930 · Phase 3 —3 mg NCT02906930 · Phase 3 —14 mg NCT02863328 · Phase 3 —14 mg NCT02607865 · Phase 3 —7 mg NCT02607865 · Phase 3 —3 mg NCT02607865 · Phase 3 —14 mg NCT02863419 · Phase 3 —14 mg NCT02827708 · Phase 3 —14 mg NCT03021187 · Phase 3 —7 mg NCT03021187 · Phase 3 —3 mg NCT03021187 · Phase 3 — NCT03914326 · Phase 3 — NCT02692716 · Phase 3 — NCT05035082 · Phase 4 · registry result, not featured evidence —14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence —14 mg NCT04017832 · Phase 3 · registry result, not featured evidence —7 mg NCT04017832 · Phase 3 · registry result, not featured evidence —3 mg NCT04017832 · Phase 3 · registry result, not featured evidence —14 mg NCT04109547 · Phase 3 · registry result, not featured evidence —7 mg NCT04109547 · Phase 3 · registry result, not featured evidence —3 mg NCT04109547 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence —Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence —14 mg NCT03018028 · Phase 3 · registry result, not featured evidence —7 mg NCT03018028 · Phase 3 · registry result, not featured evidence —3 mg NCT03018028 · Phase 3 · registry result, not featured evidence —14 mg NCT03015220 · Phase 3 · registry result, not featured evidence —7 mg NCT03015220 · Phase 3 · registry result, not featured evidence —3 mg NCT03015220 · Phase 3 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —40 mg NCT01923181 · Phase 2 · registry result, not featured evidence —20 mg NCT01923181 · Phase 2 · registry result, not featured evidence —10 mg NCT01923181 · Phase 2 · registry result, not featured evidence —5 mg NCT01923181 · Phase 2 · registry result, not featured evidence —2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 8.2%j NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results0%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 0.8%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 20.6% NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 5.2% NCT05413369 · Phase 3 · registry result, not featured evidence 3.9%Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence 10.2%Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT02058160 · Phase 3 · registry result, not featured evidence 3.8%Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 3.9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 4.5% NCT01798706 · Phase 3 · registry result, not featured evidence 3.7% NCT01768559 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 1.5% NCT01169779 · Phase 3 · registry result, not featured evidence 7.6% NCT00975286 · Phase 3 · registry result, not featured evidence 7.7% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 1.9% NCT00976937 · Phase 3 · registry result, not featured evidence 14% NCT00715624 · Phase 3 · registry result, not featured evidence 10.1% NCT00713830 · Phase 3 · registry result, not featured evidence —Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 13%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 9.9%Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 2.8%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.1%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.5% NCT00866658 · Phase 3 · registry result, not featured evidence 2.1%20 µg NCT01596504 · Phase 2 · registry result, not featured evidence —20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 5.6% NCT01476475 · Phase 2 · registry result, not featured evidence 0% NCT01175473 · Phase 2 · registry result, not featured evidence | 1.1%14 mgk NCT02906930 · Phase 3 show 39 more results1.7%7 mg NCT02906930 · Phase 3 2.9%3 mg NCT02906930 · Phase 3 6.6%14 mg NCT02863328 · Phase 3 9.5%14 mg NCT02607865 · Phase 3 10.1%7 mg NCT02607865 · Phase 3 13.7%3 mg NCT02607865 · Phase 3 10.9%14 mg NCT02863419 · Phase 3 10.4%14 mg NCT02827708 · Phase 3 6.6%14 mg NCT03021187 · Phase 3 10.5%7 mg NCT03021187 · Phase 3 13.6%3 mg NCT03021187 · Phase 3 47.9% NCT03914326 · Phase 3 18.9% NCT02692716 · Phase 3 10.2% NCT05035082 · Phase 4 · registry result, not featured evidence 9.9%14 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 8.2%50 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 10.7%25 mg once daily NCT04707469 · Phase 3 · registry result, not featured evidence 3%14 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.1%7 mg NCT04017832 · Phase 3 · registry result, not featured evidence 4.4%3 mg NCT04017832 · Phase 3 · registry result, not featured evidence 3.9%14 mg NCT04109547 · Phase 3 · registry result, not featured evidence 7.7%7 mg NCT04109547 · Phase 3 · registry result, not featured evidence 4.6%3 mg NCT04109547 · Phase 3 · registry result, not featured evidence 9.5%Oral Semaglutide Flex- Main Phase NCT02849080 · Phase 3 · registry result, not featured evidence 14.2%Oral Semaglutide Flex- Sustainabil NCT02849080 · Phase 3 · registry result, not featured evidence 9%Oral Semaglutide Flex- Switch NCT02849080 · Phase 3 · registry result, not featured evidence 0%14 mg NCT03018028 · Phase 3 · registry result, not featured evidence 6.1%7 mg NCT03018028 · Phase 3 · registry result, not featured evidence 4.1%3 mg NCT03018028 · Phase 3 · registry result, not featured evidence 5.4%14 mg NCT03015220 · Phase 3 · registry result, not featured evidence 3%7 mg NCT03015220 · Phase 3 · registry result, not featured evidence 6.9%3 mg NCT03015220 · Phase 3 · registry result, not featured evidence 1.4%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 7.1%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 4.3%40 mg NCT01923181 · Phase 2 · registry result, not featured evidence 0%20 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%10 mg NCT01923181 · Phase 2 · registry result, not featured evidence 2.9%5 mg NCT01923181 · Phase 2 · registry result, not featured evidence 1.4%2.5 mg NCT01923181 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | j nausea 28.6% nasopharyngitis 15.4% diarrhoea 15.1% NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 31 more resultsnausea 20.2% (placebo 3.3%) headache 7.6% (placebo 8.2%) vomiting 6.7% (placebo 0%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 24.2% (placebo 3.3%) headache 8.3% (placebo 8.2%) dizziness 7.5% (placebo 3.3%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 21.7% (placebo 5.9%) hypoglycaemia 20.1% (placebo 18.3%) dizziness 8.5% (placebo 6.3%) NCT01147250 · Phase 3 hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 17.2% covid-19 13.4% nausea 12.1% NCT05413369 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.8% nausea 8.6% diarrhoea 5.5% NCT02787551 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% nausea 9.2% diarrhoea 7.3% NCT02787551 · Phase 3 · registry result, not featured evidence mild asymptomatic hypoglycaemia 33.3% hypercholesterolaemia 22.2% mild gastrointestinal complaints 22.2% NCT02168491 · Phase 3 · registry result, not featured evidence · combination nausea 10.4% nasopharyngitis 8.8% headache 5.8% NCT02058160 · Phase 3 · registry result, not featured evidence nausea 9.6% diarrhoea 9% upper respiratory tract infection 7% NCT02058147 · Phase 3 · registry result, not featured evidence nausea 25% (placebo 7.5%) hypoglycaemia 17% (placebo 10.3%) diarrhoea 10.8% (placebo 7.5%) NCT01798706 · Phase 3 · registry result, not featured evidence hypoglycaemia 35.9% nausea 25.2% blood glucose decreased 20.1% NCT01768559 · Phase 3 · registry result, not featured evidence nausea 15.5% headache 7.1% nasopharyngitis 7.1% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 14.7% nasopharyngitis 9.8% hypoglycaemia 6.7% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 16.3% (placebo 2.6%) hypoglycaemia 9.2% (placebo 4.6%) dizziness 8.7% (placebo 4.1%) NCT01169779 · Phase 3 · registry result, not featured evidence hypoglycaemia 27.4% (placebo 19.3%) nausea 27.4% (placebo 4.9%) headache 9.9% (placebo 3.6%) NCT00975286 · Phase 3 · registry result, not featured evidence nausea 26% (placebo 13.7%) nasopharyngitis 16.4% (placebo 14.9%) headache 13.3% (placebo 11.8%) NCT00763815 · Phase 3 · registry result, not featured evidence nausea 24.7% (placebo 10.6%) headache 16.5% (placebo 23.5%) vomiting 15.7% (placebo 3.5%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 25.1% (placebo 10.6%) headache 19.2% (placebo 23.5%) diarrhoea 15.3% (placebo 11.8%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 17.7% headache 12.7% diarrhoea 8.9% NCT00976937 · Phase 3 · registry result, not featured evidence hypoglycaemia 42.1% (placebo 40.7%) nausea 29.3% (placebo 9.6%) headache 12.5% (placebo 10.2%) NCT00715624 · Phase 3 · registry result, not featured evidence nausea 28% (placebo 8.8%) hypoglycaemia 24.4% (placebo 19.3%) nasopharyngitis 15.9% (placebo 20.4%) NCT00713830 · Phase 3 · registry result, not featured evidence nausea 37.9% (placebo 8.1%) vomiting 18% (placebo 0.6%) diarrhoea 14.9% (placebo 13.1%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 29.2% (placebo 8.1%) vomiting 13% (placebo 0.6%) headache 12.4% (placebo 12.5%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 50% nasopharyngitis 36.1% decreased appetite 19.4% NCT00905255 · Phase 3 · registry result, not featured evidence nausea 36.4% nasopharyngitis 27.3% decreased appetite 18.2% NCT00905255 · Phase 3 · registry result, not featured evidence hypoglycaemia 43.5% (placebo 23.6%) nausea 39.6% (placebo 4.5%) vomiting 18.2% (placebo 1.9%) NCT00866658 · Phase 3 · registry result, not featured evidence 20 µg decreased appetite 18.8% nausea 18.8% nasopharyngitis 12.5% NCT01596504 · Phase 2 · registry result, not featured evidence nausea 7.5% nasopharyngitis 5.6% headache 5% NCT01476475 · Phase 2 · registry result, not featured evidence nausea 22.1% decreased appetite 18.2% headache 11.7% NCT01175473 · Phase 2 · registry result, not featured evidence | 14 mgk nausea 16% (placebo 5.6%) vomiting 6.9% (placebo 2.2%) decreased appetite 5.1% (placebo 0.6%) NCT02906930 · Phase 3 show 38 more results7 mg nasopharyngitis 6.3% (placebo 3.4%) headache 5.7% (placebo 5.1%) diarrhoea 5.1% (placebo 2.2%) NCT02906930 · Phase 3 3 mg diarrhoea 8.6% (placebo 2.2%) nausea 8% (placebo 5.6%) nasopharyngitis 5.7% (placebo 3.4%) NCT02906930 · Phase 3 14 mg nausea 19.3% (placebo 3.5%) diarrhoea 15.1% (placebo 7.7%) nasopharyngitis 14.4% (placebo 10.6%) NCT02863419 · Phase 3 14 mg nausea 19% (placebo 7.5%) constipation 11.7% (placebo 3.7%) vomiting 11.7% (placebo 1.2%) NCT02827708 · Phase 3 14 mg nausea 22.7% (placebo 7.1%) diarrhoea 14.4% (placebo 6%) decreased appetite 12.7% (placebo 1.1%) NCT03021187 · Phase 3 7 mg nausea 16.6% (placebo 7.1%) diarrhoea 12.2% (placebo 6%) nasopharyngitis 11.6% (placebo 14.7%) NCT03021187 · Phase 3 3 mg nasopharyngitis 14.7% (placebo 14.7%) nausea 11.4% (placebo 7.1%) diarrhoea 8.7% (placebo 6%) NCT03021187 · Phase 3 diabetic retinopathy 19.5% (placebo 19.3%) covid-19 15.7% (placebo 16.1%) nausea 7.1% (placebo 1.3%) NCT03914326 · Phase 3 14 mg once daily nausea 18% diarrhoea 12.4% covid-19 11.8% NCT04707469 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 27.3% vomiting 18.2% diarrhoea 14.2% NCT04707469 · Phase 3 · registry result, not featured evidence 25 mg once daily nausea 27.2% vomiting 17% diarrhoea 12.9% NCT04707469 · Phase 3 · registry result, not featured evidence 14 mg diarrhoea 13.3% nausea 12.2% decreased appetite 9.4% NCT04017832 · Phase 3 · registry result, not featured evidence 7 mg nausea 10.9% diarrhoea 8.9% decreased appetite 8.4% NCT04017832 · Phase 3 · registry result, not featured evidence 3 mg nausea 10% diarrhoea 8.3% upper respiratory tract infection 7.2% NCT04017832 · Phase 3 · registry result, not featured evidence 14 mg decreased appetite 10.9% (placebo 0%) diarrhoea 9.3% (placebo 1.5%) upper respiratory tract infection 7% (placebo 4.6%) NCT04109547 · Phase 3 · registry result, not featured evidence 7 mg diarrhoea 9.2% (placebo 1.5%) upper respiratory tract infection 9.2% (placebo 4.6%) lipase increased 8.5% (placebo 0%) NCT04109547 · Phase 3 · registry result, not featured evidence 3 mg upper respiratory tract infection 8.5% (placebo 4.6%) lipase increased 5.4% (placebo 0%) nausea 4.6% (placebo 1.5%) NCT04109547 · Phase 3 · registry result, not featured evidence nausea 20.9% nasopharyngitis 10.3% headache 9.9% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 22.9% nasopharyngitis 13.4% diarrhoea 11.5% NCT02849080 · Phase 3 · registry result, not featured evidence nausea 17% diarrhoea 10% nasopharyngitis 7% NCT02849080 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 18.8% (placebo 28.6%) constipation 12.5% (placebo 6.1%) decreased appetite 12.5% (placebo 0%) NCT03018028 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 16.3% (placebo 28.6%) constipation 12.2% (placebo 6.1%) nausea 10.2% (placebo 2%) NCT03018028 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 20.4% (placebo 28.6%) constipation 10.2% (placebo 6.1%) periarthritis 10.2% (placebo 4.1%) NCT03018028 · Phase 3 · registry result, not featured evidence 14 mg nasopharyngitis 30% constipation 15.4% nausea 9.2% NCT03015220 · Phase 3 · registry result, not featured evidence 7 mg nasopharyngitis 29.5% constipation 12.1% decreased appetite 9.1% NCT03015220 · Phase 3 · registry result, not featured evidence 3 mg nasopharyngitis 26% constipation 9.2% influenza 6.9% NCT03015220 · Phase 3 · registry result, not featured evidence 40 mg nausea 33.8% (placebo 1.4%) vomiting 19.7% (placebo 4.2%) decreased appetite 14.1% (placebo 1.4%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 35.7% (placebo 1.4%) vomiting 22.9% (placebo 4.2%) diarrhoea 17.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 40 mg nausea 32.9% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 15.7% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 20 mg nausea 35.7% (placebo 1.4%) diarrhoea 20% (placebo 9.9%) vomiting 17.1% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 10 mg nausea 33.3% (placebo 1.4%) diarrhoea 23.2% (placebo 9.9%) vomiting 20.3% (placebo 4.2%) NCT01923181 · Phase 2 · registry result, not featured evidence 5 mg nausea 14.3% (placebo 1.4%) headache 12.9% (placebo 5.6%) diarrhoea 10% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence 2.5 mg nausea 12.9% (placebo 1.4%) nasopharyngitis 8.6% (placebo 12.7%) diarrhoea 7.1% (placebo 9.9%) NCT01923181 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 24 weeks versus 104 weeks.
- eAssessment timepoints differ: 24 weeks versus 68 weeks.
- fTrial phases differ: Phase 2 versus Phase 3.
- gAssessment timepoints differ: 4 weeks versus 26 weeks.
- hAssessment timepoints differ: 24 weeks versus 52 weeks.
- iAssessment timepoints differ: 8 weeks versus 104 weeks.
- jPopulation comparability has not been reviewed for 32 of these studies.
- kPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
lixisenatide
show 10 more results
show 9 more results
show 15 more results
show 8 more results
show 1 more result
show 3 more results
+ 59 further endpoints in the CSV export.
Semaglutide (Rybelsus)
show 11 more results
show 9 more results
show 43 more results
show 49 more results
show 10 more results
show 2 more results
show 11 more results
show 10 more results
show 10 more results
show 10 more results
show 36 more results
show 39 more results
+ 114 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · Semaglutide (Rybelsus)'s landscape